drugset / Trial / NCT03613597

Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung Cancer

NCT03613597

Phase 2 Unknown 118 enrolled Guizhou Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized phase II study compare survival outcomes and toxicity of two chemotherapy regimens (etoposide plus lobaplatin or etoposide plus cisplatin) in combination with concurrent thoracic radiation therapy (TRT) for limited stage small cell lung cancer.

Timeline

Start
2018-06-01
Primary completion
2021-01-01
Completion
2022-01-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cisplatin Other / unclassified
Subject Etoposide Small molecule
Subject Lobaplatin Small molecule